Circadian variations in blood pressure: Implications for chronotherapeutics

被引:25
作者
Hassler C. [1 ]
Burnier M. [1 ]
机构
[1] Div. of Hypertension/Vascular Med., Department of Medicine, Centre Hospitalier Univ. Vaudois, Lausanne 1011, Av. P. Decker
关键词
Losartan; Ramipril; Ambulatory Blood Pressure; Telmisartan; Ambulatory Blood Pressure Monitoring;
D O I
10.2165/00129784-200505010-00002
中图分类号
学科分类号
摘要
The management of hypertensive patients usually ignores or gives little credit to the biologic rhythms inherent to the disease process and their potential clinical implications. The development of ambulatory blood pressure monitoring and the rapidly growing popularity of home blood pressure measurements by patients have now generated a series of new clinical questions that are directly linked to the chronobiology of the cardiovascular system, such as the clinical interpretation of a blunted nocturnal fall in blood pressure or the difficulty of achieving adequate blood pressure control in the morning. Today, there is growing evidence that night-time blood pressure, and particularly the absence of a decrease in sleep blood pressure, contributes to the occurrence of target organ damages, and that the early morning rise in blood pressure increases the risk of developing cardiovascular events, including stroke, perhaps independently of 24-hour blood pressure levels. On the basis of these observations, it may be necessary to reconsider the way antihypertensive drugs are prescribed in order to obtain smooth, 24-hour blood pressure control, respecting the circadian pattern of blood pressure. Several approaches exist, including the use of drugs that lower blood pressure around the clock and respect the diurnal rhythm. Preliminary studies performed with such agents have provided interesting results. However, there is a clear need for large clinical trials demonstrating the clinical superiority of this approach. In any case, a better understanding of the importance of the circadian variations of blood pressure could certainly have a major impact on our view of the therapeutic management of hypertensive patients. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码:7 / 15
页数:8
相关论文
共 79 条
[51]  
Morgan T., Brunner H.R., Aubert J.F., Et al., The relationship of blood pressure to cardiac hypertrophy: Experimental studies in rats, Clin. Exp. Hypertens., 19, pp. 827-841, (1997)
[52]  
Morgan T., Brunner H.R., Aubert J.F., Et al., Cardiac hypertrophy depends upon sleep blood pressure: A study in rats, J. Hypertens, 18, pp. 445-451, (2000)
[53]  
Pechere-Bertschi A., Nussberger J., Decosterd L., Et al., Renal response to the angiotensin II receptor subtype 1 irbesartan versus enalapril in hypertensive patients, J. Hypertens., 16, pp. 385-393, (1998)
[54]  
Forclaz A., Maillard M., Nussberger J., Et al., Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor?, Hypertension, 41, pp. 31-36, (2003)
[55]  
McIntyre M., Caffe S.E., Michalak R.A., Et al., Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension, Pharmacol. Ther., 74, 2, pp. 181-194, (1997)
[56]  
Neutel J., Smith D.H., Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: Meta-analysis of a clinical database, J. Clin. Hypertens., 5, 1, pp. 58-63, (2003)
[57]  
Pitt B., Poole-Wilson P.A., Segal R., Et al., Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The Losartan Heart Failure Survival Study ELITE II, Lancet, 355, pp. 1582-1587, (2000)
[58]  
Dickstein K., Kjekshus J., Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial, Lancet, 360, pp. 752-760, (2002)
[59]  
Dahlof B., Devereux R.B., Kjeldsen S.E., Et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol, Lancet, 359, pp. 995-1003, (2002)
[60]  
Brenner B.M., Cooper M.E., de Zeeuw D., Et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N. Engl. J. Med., 345, pp. 861-869, (2001)